as mentioned in The approval of Brodalumab is a binary negative event for Valeant because of short-term and long-term concerns in the commercialization of the drug.
If the drug is approved with strong warning labels or heavy FDA restrictions, some of its priced-in value will erode.
However, warning labels and other restrictions may come as a negative surprise.
There is also strong possibility of an adverse market reaction to warning labels or other restrictions from the FDA with the approval.
The only binary event for Feb 16th is warning labels.
referring to Depending on the share price, Papa will earn a lot of money if things go well by the end of 2020.
A lot has happened at Valeant (NYSE:VRX) which caused its share price to fall dramatically from ~$250 a share to ~$14 a share at the time of writing.
Let’s take a look at Valeant’s current bond prices, bond prices are often a great indicator for a company’s financial health.
Another downward guidance would probably send Valeant’s share price to even lower levels.
New CEO and management teamIt’s no surprise that Pearson had to leave Valeant after the dramatic share price crash.
referring to Senator Bernie Sanders recently urged the federal government to allow Americans to purchase pharmaceutical drugs from Canada where they are cheaper.
In my opinion, the dissent from Booker and other lawmakers on importing drugs is a big victory for Valeant.
A Stinging Defeat For Senator SandersIn 2015 Senator Bernie Sanders ranted about U.S. soldiers deserving access to cheaper HCV treatments.
Despite promises to repair its public image as a price-gouger, Valeant has continued to raise prices for certain drugs.
The Senate Special Committee on Aging suggested that importing drugs could be an important tool to combat price hikes from Valeant and/or other price gougers.
about the details read more from here
This content may collect you by Luaren Colin